“…This CAD technology has been tested in clinical trials aimed to distinguish benign from malignant tissue in the breast and the ovary, but its widespread clinical use has not been adopted for these tissues [10][11][12]. According to published data, it has the potential to predict cancer lesion location within the prostate at 90% sensitivity and 72% specificity for tumors that are more than 0.2 cm 3 in volume compared to RP specimens [1,9].…”